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Abstract: Anticoagulation with unfractionated heparin during
extracorporeal membrane oxygenation (ECMO) is common, but
alternative agents are being evaluated for safety and efﬁcacy. The
objective of this analysis was to assess if a comprehensive bivalirudin dosing and monitoring protocol effectively guides dose
adjustments and monitoring of bivalirudin in patients during
ECMO. Our analysis included 11 patients who received bivalirudin during ECMO therapy and had dosing managed using our
hospital derived protocol. Patients treated over a 1-year period
were included in this retrospective analysis. Clinical characteristics and changes in activated partial thromboplastin time (aPTT)
were evaluated from medical records to determine the efﬁcacy of
the dosing protocol. ECMO was initiated for acute respiratory
distress syndrome in eight (72.7%) patients and for cardiac arrest
in three (27.3%) patients. A total of 178 protocol guided dose
adjustments were made during the study. Among the dose

adjustments, 56 (31.5%) attained the protocol predicted aPTT
level change, 96 (53.9%) of the measured aPTT changes were
less than predicted, and 26 (14.6%) of the measured aPTT
changes were more than predicted. On average, patients were
within their deﬁned therapeutic aPTT target range 66.3% of the
time. All patients reached their designated aPTT target range
within the ﬁrst 24 hours of therapy. Signiﬁcant bleeding was
documented in eight (72.7%) patients. No clinically evident
thromboembolic events were identiﬁed in vivo while cannulated. This analysis suggests that bivalirudin can be managed
using a dosing protocol to provide anticoagulation therapy to
patients during ECMO and can provide foundational guidance
for dose adjustment and monitoring for other institutions.
Keywords: extracorporeal membrane oxygenation, blood,
anticoagulation, bivalirudin, pharmacology. J Extra Corpor
Technol. 2018;50:161–6

Extracorporeal membrane oxygenation (ECMO) is a life
support system that provides pulmonary and/or circulatory
support for patients experiencing a variety of disease states,
such as hypoxemic or hypercapnic respiratory failure,
cardiac arrest, cardiogenic shock, and cardiopulmonary
distress (1–2). During ECMO, patients are at risk for
thromboembolic events due to the blood’s exposure to the
foreign surfaces of the system circuit which necessitates the
use of anticoagulants. Patients are often anticoagulated
using a continuous intravenous infusion of heparin which
places them at a concomitant increased risk of bleeding (3–5).

The prevalence of thromboembolic events reported in
previous studies has been variable, ranging from 8.7 to 46.1%
(5–7). Systemic anticoagulation is commonly used to reduce
the risk of thromboembolic events from occurring in the patient and/or the machine’s circuit. Monitoring of anticoagulation is necessary to evaluate efﬁcacy of therapy and to
maintain patient safety and hemodynamic stability (8–11).
Unfractionated heparin is the primary anticoagulant mentioned in guidelines published by the extracorporeal life support organization and is frequently used during ECMO (12).
Newer anticoagulants, such as direct thrombin inhibitors,
are being used as an alternative to unfractionated heparin
(13–15). Direct thrombin inhibitors directly bind to active
sites on thrombin, providing a more predicable pharmacokinetic proﬁle and a greater reduction in thrombin
compared with unfractionated heparin (16). Direct
thrombin inhibitors are short-acting which allows for rapid
titration to achieve desired anticoagulation (17). Heparininduced thrombocytopenia or other immune mediated
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thrombocytopenias are not seen with direct thrombin inhibitors (18). Only two intravenous direct thrombin inhibitors are commercially available: argatroban and
bivalirudin. Need for dose adjustment in patients with
hepatic impairment, false elevation of prothrombin time
and international normalized ratio, and cost are obstacles
for the use of argatroban. There has been preliminary data
regarding the use of bivalirudin as an anticoagulant during
ECMO; however, there is limited published data or protocols about bivalirudin dosing and monitoring in ECMO.
The objective of this analysis was to assess if a hospital
derived comprehensive bivalirudin dosing and monitoring
protocol could safely and effectively guide dose adjustments and monitoring of bivalirudin in patients during
ECMO.

MATERIALS AND METHODS
This descriptive retrospective analysis was conducted at
a single center community hospital in Fort Wayne, Indiana,

Figure 1. Bivalirudin dosing and monitoring during ECMO protocol.
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following the implementation of a bivalirudin based anticoagulation protocol for patients on ECMO.
All patients who were placed on ECMO during a 1-year
period were evaluated. Patients were evaluated to be included in the study if they were placed on ECMO following
the protocol’s implementation (Figure 1). This analysis
excluded patients who were not candidates for anticoagulation therapy during ECMO and patients who did
not have at least one protocol-based dose adjustment
during therapy.
The following data were collected for each eligible patient: basic demographic information (age, gender, height,
weight), indication for ECMO therapy, bivalirudin dosing
information (weight used for initial dose calculation, renal
function, infusion rate adjustments, and bolus dosing information), baseline and subsequent activated partial
thromboplastin time (aPTT) values (measured 2 hours
after infusion initiation, 1 hour after a bolus given, 2 hours
after non-bolus dose adjustments, and every 4 hours if
within target range), highest and lowest complete blood
count levels during therapy, continuous renal replacement
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(CRRT) therapy usage, and thromboembolic or signiﬁcant
bleeding events if they occurred. Signiﬁcant thromboembolic events were deﬁned as events requiring ECMO
therapy to be suspended to allow for replacement of oxygenator and/or tubing if there was a sufﬁcient decrease in
ﬂow or thromboembolic events identiﬁed in vivo by
a computerize tomography scan. Signiﬁcant bleeding was
deﬁned as any bleeding event that warranted treatment
including, but not limited to, blood transfusions, surgical
interventions, or use of hemostatic agents, and any need to
adjust the infusion rate of bivalirudin to target the lower
aPTT range.
This analysis had two co-primary outcomes. The ﬁrst coprimary outcome was the percentage of time patients were
maintained within the deﬁned aPTT target range to achieve
a targeted anticoagulated state. The second co-primary
outcome was to determine the accuracy of dose adjustments by comparing the predicted aPTT change utilizing the
protocol and the actual change in aPTT values following the
dose adjustments. The primary safety outcomes for this
analysis were the occurrence of signiﬁcant bleeding and
thromboembolic events. In some cases of signiﬁcant bleeding, anticoagulation was continued if the patient-speciﬁc
details deemed it clinically necessary. If anticoagulation
was continued, the need for a lower aPTT target range was
assessed and per protocol, the infusion could be held if
desiring a decrease in aPTT by more than 40 seconds.
Secondary outcomes included percentage of time aPTT was
within the upper half of target range, percentage of time the
aPTT was within the lower half of the target range, percentage of aPTT levels lower and higher than the target
range, time to achieve therapeutic aPTT, length and outcome
of ECMO treatment, and mortality rates.
Patients were originally assigned a goal aPTT range for
anticoagulation therapy as determined to be appropriate by
the physician initiating ECMO therapy. Physicians could
initiate goal therapy to target an aPTT monitoring goal
of 40–60 seconds, 50–70 seconds, or 60–80 seconds. All
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patients were started on the same initial dose and no initial
bolus dose was given per protocol. Following the initiation
of therapy, aPTT was checked after 2 hours and then every
4 hours thereafter. After a follow-up aPTT level had been
collected, the patient’s goal range could be increased or
decreased dependent on the physician’s clinical discretion.
New aPTT target ranges did not have to be limited to the
original predeﬁned ranges and physicians could also indicate targeting toward the higher or lower end of the
target range dependent on the clinical situation. Details of
the dosing and monitoring protocol can be found in the
supplemental information. No additional anticoagulation
was provided to the patient through sample ports or pigtails
to reduce areas of stasis.
Descriptive and frequency statistics were used to analyze
the data. All data management and statistics were performed
using Excel 2010 (Microsoft Corp., Redmond, WA).

RESULTS
A total of 15 patients were treated with ECMO during
the analysis period. After eligibility screening, four patients
were excluded: two did not receive anticoagulation therapy
during ECMO and two did not have at least one protocoldirected dose adjustment for bivalirudin therapy.
Of the 11 patients included in this analysis, eight (72.7%)
patients had an indication of acute respiratory distress
syndrome (ARDS), and three (27.3%) patients had an
indication of cardiac arrest for ECMO. Four patients underwent veno-arterial ECMO, six patients underwent
veno-venous ECMO, and one patient was started on venovenous ECMO and later transitioned to veno-arterial
ECMO. Additional demographic information can be found
in Table 1.
On average, patients spent 66.3% of time within their
deﬁned therapeutic aPTT target range. The lowest percentage of time within therapeutic range was 30.0%, and

Table 1. Baseline patient demographics and outcomes.

Case

Age
(years)

Weight
(kg)

1
2
3
4
5
6
7
8
9
10
11

41
60
22
60
47
61
56
61
16
69
74

57.1
70.4
72.5
114.1
89.4
62.7
127.7
84.1
80.7
97.9
105.0

Indication

ECMO
LOT

Hospital
LOS

AMI
ARDS
ARDS
ARDS
AMI
ARDS
ARDS
ARDS
ARDS
ARDS
AMI

4
7
4
6
4
22
21
12
17
4
8

4
19
11
30
4
50
29
19
39
9
9

CRRT

Platelet
Range
(th/mL)

Hemoglobin
Range
(g/dL)

Outcome

No
No
No
Yes
No
Yes
No
Yes
No
No
Yes

20–199
203–391
57–313
61–279
39–529
44–344
48–276
29–273
85–292
30–115
63–437

8.1–12.1
7–11.8
7.6–18.4
7.5–13.8
6.8–17.5
6.6–11.2
8.6–14.9
7.2–15.5
8.2–16.6
6–11.5
7.7–16.8

Weaned and expired
Survived
Survived
Survived
Weaned and expired
Survived
Weaned and expired
Weaned and expired
Survived
Survived
Weaned and expired

AMI, acute myocardl infarction; LOS, length of stay; LOT, length of therapy.
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the highest time within therapeutic range was 90.0%. The
most common therapeutic goal range selected as an original
target by physicians was 50–70 seconds. Only two (18.2%)
patients did not have their target aPTT goal adjusted
during ECMO treatment.
A total of 178 protocol guided dose adjustments were
made during the analysis period. Of the dose adjustments,
56 (31.5%) attained the protocol predicted aPTT level
change. Most commonly, the aPTT level change following
protocol guided dose adjustments was less than what was
predicted by the protocol. Among the dose adjustments, 96
(53.9%) were less than what the protocol predicted and 26
(14.6%) were greater than what the protocol predicted.
Adjustments made at lower infusion rates were more likely
to be less than what the protocol predicted compared with
adjustments made at higher infusions rates. Additional data
for time within designated therapeutic ranges can be found
in Table 2.
In addition to changing the aPTT target range, physicians
could also specify to target the lower end or higher end of
the target range. Targeting the lower end of the target
range was commonly performed if the patient had significant bleeding or clinical discretion that the patient may be
likely to bleed at higher aPTT levels. Targeting the higher
end of the target range was commonly performed if clots or
ﬁbrin strands were seen in the oxygenator or circuit. For
aPTT levels that were within the patients’ predeﬁned target
range, 47.3% of levels were speciﬁc to the lower half of the
target range and 52.7% of levels were speciﬁc to the higher
end of the target range.
Patient time to therapeutic goal varied. There were three
(27.7%) patients who reached goal from the initial bivalirudin infusion dose, 2.5 mcg/kg/min, as indicated by the ﬁrst
aPTT level drawn after the start of the infusion. The other
eight patients had a supratherapeutic aPTT after the start of
the infusion and required dose adjustments to get them into
their deﬁned therapeutic range. By 14 hours after the start of
the infusion, eight patients (72.7%) reached their target goal
range. All patients reached their target aPTT goal range
within the ﬁrst 24 hours of therapy.

Signiﬁcant bleeding was documented in eight (72.7%)
patients. The most common documented bleeding event
was from cannulation sites of the ECMO circuit. Bleeding
was also noted from other tubing sites. One patient had
documented bleeding from a pulmonary source identiﬁed
via their endotracheal tube and another patient had
a gastrointestinal bleed identiﬁed via their orogastric tube.
Neither patient required intervention to stop or prevent
additional bleeding. One patient was admitted with open
sores in the mouth before ECMO therapy. During treatment, the oral sores began to bleed and the patient required
packing with ﬁbrin sealant to stop the bleeding.
All patients included in our analysis had documented
clotting within the oxygenator and/or ﬁbrin strand formation pre-oxygenator. Clots and ﬁbrin stands were
monitored routinely with every shift change and aPTT
laboratory draw. No patients required ECMO therapy to
be stopped because of signiﬁcant obstruction of ﬂow in the
tubing or oxygenator. Two patients were identiﬁed as
having thromboembolic events, but both occurred after decannulation and discharge from the hospital. One patient
was readmitted 1 week later for superior vena cava
thrombus and one patient was readmitted 2 months later
for bilateral lower extremity deep vein thromboses.
The average length of ECMO was 9.9 days (6SD 6.6)
with an average length of hospitalization of 20.3 days
(614.4). Death occurred in ﬁve (45.5%) patients during
their admission. All deaths occurred in the hospital following the decision for patients to be terminally weaned
from ventilator support and other supportive care, including ECMO therapy. All six of the patients discharged
from the hospital were still living 90 days after the discharge
date.

DISCUSSION
This analysis found that changes in aPTT levels could
be predicted using pre-speciﬁed adjustment rates for
bivalirudin. These results suggest that anticoagulation

Table 2. Protocol efﬁcacy per patient case.
Case

No. aPTT Collected

1
2
3
4
5
6
7
8
9
10
11

10
47
20
39
23
133
125
90
93
27
53
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No. aPTT in Target Range
(% of time in range)
9
35
6
26
11
106
86
61
78
15
34

(90.0)
(74.5)
(30.0)
(66.7)
(47.8)
(79.7)
(68.8)
(67.8)
(83.9)
(55.6)
(64.2)

No. aPTT Higher than Target Range
(% of time in range)
1
7
7
9
11
17
19
20
14
5
7

(10.0)
(14.9)
(35.0)
(23.1)
(47.8)
(12.8)
(15.1)
(22.2)
(15.1)
(18.5)
(13.2)

No. aPTT Lower than Target Range
(% of time in range)
0
5
7
4
1
10
20
9
1
7
12

(0.0)
(10.6)
(35.0)
(10.2)
(4.4)
(7.5)
(16.1)
(10.0)
(1.0)
(25.9)
(22.6)

BIVALIRUDIN ANTICOAGULATION DOSING PROTOCOL FOR ECMO
needs during ECMO therapy can be accomplished with
bivalirudin using a protocol to guide dose adjustments and
monitoring.
Our ﬁndings serve to expand on the limited data
available for the use and management of bivalirudin as
anticoagulation therapy during ECMO therapy. Anticoagulation therapy during ECMO has traditionally been
managed with intravenous heparin infusions. Although
some data have been published about the use of bivalirudin as an anticoagulant in ECMO, the data has been
limited. Additional data on how to manage and adjust
bivalirudin when it is used in anticoagulation therapy has
yet to be published.
In our institution, we designed a protocol to manage the
dose adjustment of bivalirudin to reduce possible confounding factors that may occur if dose adjustment occurred on a patient to patient basis; thus, all patients were
managed in the same fashion allowing for homogenous
data to assess how effective our protocol was and if it could
effectively manage bivalirudin. All patients were assigned
a target aPTT range before starting anticoagulation therapy. Our analysis included patients for both ARDS and
cardiac arrest. Patient demographics were also widely
varied allowing the protocol to be used in a fairly heterogenous population. Despite our small analysis population,
having a varied patient population allows for the application
and generalizability of a bivalirudin dose adjustment protocol that may be applied to larger populations.
Our analysis has some limitations. First, the sample size
was small during the approximate year of observation for
the protocol after it was implemented. Our analysis also
excluded two patients who did not receive anticoagulation
therapy during ECMO therapy. One patient transferred
from the hospital before having anticoagulation therapy
initiated. The second patient had anticoagulation therapy
withheld because of preexisting pancytopenia that predisposed the patient to a high bleeding risk. Two other
patients who received bivalirudin were excluded because
they did not have at least one protocol-managed dose
adjustment. For one patient, care was withdrawn before
having a dose adjustment completed. The other patient was
started on bivalirudin, however, following the ﬁrst aPTT,
the value was supratherapeutic and elevated beyond being
detectable by the laboratory. Follow-up aPTT laboratory
draws were completed on a scheduled basis for 32 hours,
then the patient was weaned and withdrawn from supportive care. Despite a small patient population, we felt the
sample size reported was signiﬁcant considering the limited
amount of data available on the subject. Our ﬁndings are
introductory and need to be conﬁrmed in a larger patient
population.
Secondly, the reported number of times an adjustment
in the infusion rate achieved a predicted change in aPTT
was only 31.5%. During analysis of the data, it was
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discovered that at lower infusion rates, the dose adjustments made were less accurate than dose adjustments
made when the infusion rate was higher. Because our dose
adjustments were percentage based, lower infusion rates
would have a smaller adjustment in the dose compared
with higher infusion rates where the dose changes would
be more signiﬁcant. It was found that changes in the aPTT
were most commonly less than what was predicted by the
protocol. At the time our hospital’s bivalirudin dosing
protocol was created and implemented there was limited
data available for dosing bivalirudin in ECMO patients
and it was felt that more conservative dose adjustments
where the actual change was less than the predicted was
preferable so we were not over-anticoagulating our patients. Following any dose adjustments of bivalirudin, the
aPTT was rechecked in 2 hours, and doses could be readjusted again if out of range. Thus, patients were not out
of their goal range for long periods of time if a dose
adjustment did not achieve its desired or predicted
change.
Third, the reported amount of time patients were
maintained in their designated aPTT therapeutic range was
66.3% of the time. This may be construed to mean that
patients were ineffectively managed 33.7% of the time,
however, our protocol did allow for clinical discretion to
override the need for dose adjustment if the patient was
only slightly out of range. For the purpose of our analysis,
we used hard set ranges to determine the time within
therapeutic range; however, it should be noted that patients
were at times maintained at an aPTT that was either
subtherapeutic or supratherapeutic if it was clinically
perceived to be beneﬁcial to the patient. One example was
for a patient with a target aPTT range of 50–70. The patient
had clotting in the ECMO machine circuit and one aPTT
resulted at 71.2 seconds. Despite the aPTT being elevated
higher than the goal range, the patient was continued at the
same infusion rate to reduce the risk of further clot formation. During the analysis period, patients were maintained at either a subtherapeutic level or supratherapeutic
level as directed a total of 28 times.
Last, our health system used aPTT levels to guide dose
adjustment of bivalirudin. There is little information for
direct correlation between the anticoagulation effect of
bivalirudin and reported aPTT levels. Other health systems
may use different laboratory values to measure the effects
of parenteral direct thrombin inhibitors such as activated
clotting time, ecarin chromogenic assay, dilute thrombin
time test, or prothrombinase-induced clotting time test.
Activated clotting time laboratory draws are not commonly
used on the patient ﬂoors at our institution and the other
laboratory assessment tools are not available at our health
system. This may decrease the generalizability of our
protocol to other institutions that use these other laboratory values and not aPTT levels.
J Extra Corpor Technol. 2018;50:161–6
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In conclusion, we demonstrated that bivalirudin can be
managed using a dose adjustment protocol during ECMO
therapy to provide anticoagulation therapy with minimal
bleeding events and no clinically evident thromboembolic
complications in vivo while cannulated. Although our dose
adjustment only resulted in the predicted aPTT change 31.5%
of the time, we believe the conservativeness of our dose
adjustment prevented over anticoagulation while still not
placing the patient at risk of clinically evident thromboembolic complications. Our data helps expand on the limited
data available for dosing and adjusting bivalirudin in ECMO
patients and may help provide a foundational protocol for
other health systems looking to modify or create a bivalirudin
anticoagulation dosing policy for ECMO patients.
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